Literature DB >> 9578415

Melanoma cell lines from different stages of progression and their biological and molecular analyses.

K Satyamoorthy1, E DeJesus, A J Linnenbach, B Kraj, D L Kornreich, S Rendle, D E Elder, M Herlyn.   

Abstract

The biological and molecular characteristics of cell lines from metastatic melanomas have been extensively studied but less is known about cells from the biologically earliest stage of primary melanoma. The overall success rate of establishing permanent cell lines from such lesions is only 10% of that for biologically late primary or metastatic melanomas, although our laboratory now has eight cell lines available. The cells are immortal but show reduced or no proliferation in soft agar and immunodeficient mice when compared with primary melanomas from the biologically advanced vertical growth phase. Metastatic melanoma cell lines from patients with familial melanoma or xeroderma pigmentosum are biologically similar to those from patients with spontaneous melanomas. Irrespective of the malignant stages, deletions and mutations can occur in exons 1-3 of the p16INK4A gene. DNA fingerprinting was then employed to demonstrate the uniqueness of individual cell lines and to confirm the identity of cell lines derived from same patients. These cell lines are an excellent resource to investigate melanoma progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9578415

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  68 in total

1.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

2.  A simple engineered platform reveals different modes of tumor-microenvironmental cell interaction.

Authors:  Chentian Zhang; Elizabeth M Shenk; Laura C Blaha; Byungwoo Ryu; Rhoda M Alani; Mario Cabodi; Joyce Y Wong
Journal:  Biofabrication       Date:  2015-12-30       Impact factor: 9.954

3.  Targeting multiple key signaling pathways in melanoma using leelamine.

Authors:  Raghavendra Gowda; SubbaRao V Madhunapantula; Omer F Kuzu; Arati Sharma; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

4.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

5.  ATM couples replication stress and metabolic reprogramming during cellular senescence.

Authors:  Katherine M Aird; Andrew J Worth; Nathaniel W Snyder; Joyce V Lee; Sharanya Sivanand; Qin Liu; Ian A Blair; Kathryn E Wellen; Rugang Zhang
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

6.  Growth inhibitory effects of large subunit ribosomal proteins in melanoma.

Authors:  Gregory R Kardos; Mu-Shui Dai; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2014-06-16       Impact factor: 4.693

7.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

8.  RACK1 mediates activation of JNK by protein kinase C [corrected].

Authors:  Pablo López-Bergami; Hasem Habelhah; Anindita Bhoumik; Weizhou Zhang; Lu-Hai Wang; Ze'ev Ronai
Journal:  Mol Cell       Date:  2005-08-05       Impact factor: 17.970

9.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

10.  Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival.

Authors:  Geoffrey E Johnson; Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.